Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Developmental Therapeutics Program (DTP)
Contact DTP
Show menu
Search this site

Welcome to the Developmental Therapeutics Program

The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. Since its inception in 1955 by Congress, DTP has supported the development of more than 40 US-licensed anti-cancer agents through extensive collaborations with academic, pharmaceutical and biotechnology industries, including Paclitaxel, Romidepsin, Eribulin, Sipuleucel-T, and Dinutuximab (Ch14.18).

Today, most of DTP’s drug discovery and development services are available for academic and private researchers through applying for NCI Experimental Therapeutic program (NExT). Under this new framework, DTP continues to help academic and private sectors to overcome financial and technical barriers, particularly through supporting high-risk treatments for rare cancers, and facilitate the movement of promising therapeutic agents from scientists’ bench side to patients’ bed side.

DTP services and resources:

DTP drug discovery and pre-clinic development services

Discovery services (NCI60 screening etc.) and pre-clinical support (pharmacology, toxicology and cGMP production etc.).

DTP repositories

Synthetic compounds, natural products, biological samples and standards.

DTP databases and searching/analysis tools

Bulk DTP chemical and biological data for searching and download, COMPARE analysis.

DTP grant programs

Grants for preclinical anti-cancer drug discovery and treatment, including small molecules, natural products and biological agents.

DCTD consultations

Advice on development of small molecules, biologics, and imaging products intended for cancer patients.

Stepping Stones

Access to discrete drug development studies for NCI/DCTD grantees.

About the Acting Associate Director

Rosemarie Aurigemma, Ph.D. Rosemarie Aurigemma, Ph.D., has been a programmatic leader in drug development for over 20 years. Her tenure as the Deputy Associate Director of DTP resulted in the launch of the Stepping Stones preclinical development program as well as the initiation and expansion of biopharmaceutical manufacturing support for adoptive cell therapies. She was appointed as Acting Associate Director of the DCTD Developmental Therapeutics Program in January 2021. More…

DTP Hot Links

Highlights

What’s New